Detecting and targeting NTRK fusions and HER2 mutations in NSCLC: a clinical pathway tool
This educational tool will guide you through best practices for the detection and management of NTRK fusion-positive and HER2 mutation-positive NSCLC. This interactive pathway tools covers the various assays available for identifying HER2 mutations and NTRK gene fusions, supporting you to detect these biomarkers in your practice. Our expert faculty explain the latest advances in targeted therapies for HER2 mutation-positive and NTRK fusion–positive NSCLC, offering practical treatment recommendations. The pathway also includes extensive summaries of clinical trials to keep you updated on emerging data and novel targeted therapies.
Register to access
Learning objectives
After completing this activity, you will be able to:
- Select appropriate biomarker tests to inform treatment selection for patients with NSCLC
- Integrate new clinical data on targeted therapies into clinical practice to create individualized treatment plans for patients with biomarker-positive NSCLC
Activity overview
This algorithm module is available with video and text. The activity is best supported via a computer or mobile device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari.
